Keith L. Knutson - Publications

Affiliations: 
Immunology College of Medicine - Mayo Clinic 
Area:
Immunology, Cell Biology

95 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, ... ... Knutson KL, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. Npj Breast Cancer. 6: 4. PMID 32047850 DOI: 10.1038/s41523-020-0147-1  0.4
2019 Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31757875 DOI: 10.1158/1078-0432.CCR-19-2123  0.64
2018 Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer. Breast Cancer Research : Bcr. 20: 52. PMID 29898752 DOI: 10.1186/s13058-018-0989-8  0.64
2018 Kalli KR, Block MS, Kasi PM, Erskine CL, Hobday TJ, Dietz A, Padley D, Gustafson MP, Shreeder B, Puglisi-Knutson D, Visscher DW, Mangskau TK, Wilson G, Knutson KL. Folate Receptor Alpha Peptide Vaccine generates immunity in Breast and Ovarian Cancer Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29545464 DOI: 10.1158/1078-0432.CCR-17-2499  0.64
2017 Henle AM, Nassar A, Puglisi-Knutson D, Youssef B, Knutson KL. Downregulation of TAP1 and TAP2 in early stage breast cancer. Plos One. 12: e0187323. PMID 29091951 DOI: 10.1371/journal.pone.0187323  0.64
2016 Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp K, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt DW, Tan W, Calfa C, Pegram MD, Mittendorf EA, Perez EA. Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain. Cancer Research. PMID 27197192 DOI: 10.1158/0008-5472.CAN-15-3091  0.64
2015 Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-KappaB. Cancer Research. PMID 26567141 DOI: 10.1158/0008-5472.CAN-15-0748  0.64
2015 Escalante P, Peikert T, Van Keulen VP, Erskine CL, Bornhorst CL, Andrist BR, McCoy K, Pease LR, Abraham RS, Knutson KL, Kita H, Schrum AG, Limper AH. Combinatorial Immunoprofiling in Latent Tuberculosis Infection: Toward Better Risk Stratification. American Journal of Respiratory and Critical Care Medicine. PMID 26030344 DOI: 10.1164/rccm.201412-2141OC  0.64
2015 Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL. Tumor-infiltrating dendritic cells in cancer pathogenesis. Journal of Immunology (Baltimore, Md. : 1950). 194: 2985-91. PMID 25795789 DOI: 10.4049/jimmunol.1403134  0.64
2015 Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 73: 108-13. PMID 25743245 DOI: 10.1016/j.cyto.2015.01.035  0.64
2015 Knutson KL, Karyampudi L, Lamichhane P, Preston C. Targeted immune therapy of ovarian cancer. Cancer Metastasis Reviews. 34: 53-74. PMID 25544369 DOI: 10.1007/s10555-014-9540-2  0.64
2015 Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Research. 75: 22-30. PMID 25398436 DOI: 10.1158/0008-5472.CAN-14-2533  0.64
2014 Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer Immunology Research. 2: 962-9. PMID 24989892 DOI: 10.1158/2326-6066.CIR-14-0059  0.64
2014 Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD, Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, ... ... Knutson KL, et al. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1421-7. PMID 24740199 DOI: 10.1158/1055-9965.EPI-13-0962  0.64
2014 Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Research. 74: 2974-85. PMID 24728077 DOI: 10.1158/0008-5472.CAN-13-2564  0.64
2014 Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, ... ... Knutson KL, et al. Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. Cancer Research. 74: 3084-91. PMID 24728075 DOI: 10.1158/0008-5472.CAN-13-3198  0.64
2013 Davis JM, Knutson KL, Strausbauch MA, Green AB, Crowson CS, Therneau TM, Matteson EL, Gabriel SE. Immune response profiling in early rheumatoid arthritis: discovery of a novel interaction of treatment response with viral immunity. Arthritis Research & Therapy. 15: R199. PMID 24267267 DOI: 10.1186/ar4389  0.64
2013 Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. Plos One. 8: e80063. PMID 24244610 DOI: 10.1371/journal.pone.0080063  0.64
2013 Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE. Rheumatoid arthritis and cardiovascular disease. American Heart Journal. 166: 622-628.e1. PMID 24093840 DOI: 10.1016/j.ahj.2013.07.010  0.64
2013 Derycke MS, Charbonneau B, Preston CC, Kalli KR, Knutson KL, Rider DN, Goode EL. Toward understanding the genetics of regulatory T cells in ovarian cancer. Oncoimmunology. 2: e24535. PMID 23894717 DOI: 10.4161/onci.24535  0.64
2013 Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1730-5. PMID 23878295 DOI: 10.1158/1055-9965.EPI-12-1368  0.64
2013 Charbonneau B, Goode EL, Kalli KR, Knutson KL, Derycke MS. The immune system in the pathogenesis of ovarian cancer. Critical Reviews in Immunology. 33: 137-64. PMID 23582060 DOI: 10.1615/CritRevImmunol.2013006813  0.64
2013 Pavelko KD, Bell MP, Karyampudi L, Hansen MJ, Allen KS, Knutson KL, Pease LR. The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1087-95. PMID 23568262 DOI: 10.1038/mt.2013.52  0.64
2013 Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, ... ... Knutson KL, et al. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. Plos One. 8: e53903. PMID 23382860 DOI: 10.1371/journal.pone.0053903  0.64
2013 Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB, Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. Journal of Translational Medicine. 11: 20. PMID 23347343 DOI: 10.1186/1479-5876-11-20  0.64
2013 Henle AM, Erskine CL, Benson LM, Clynes R, Knutson KL. Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 479-88. PMID 23180824 DOI: 10.4049/jimmunol.1201264  0.64
2012 Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR. Tumor escape and progression under immune pressure. Clinical & Developmental Immunology. 2012: 641079. PMID 23316254 DOI: 10.1155/2012/641079  0.64
2012 Juskewitch JE, Platt JL, Knudsen BE, Knutson KL, Brunn GJ, Grande JP. Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammation. Scientific Reports. 2: 918. PMID 23213355 DOI: 10.1038/srep00918  0.64
2012 Erskine CL, Henle AM, Knutson KL. Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system Journal of Visualized Experiments : Jove. e3683. PMID 22895471 DOI: 10.3791/3683  0.64
2012 Davis JM, Knutson KL, Skinner JA, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. Arthritis Research & Therapy. 14: R24. PMID 22293286 DOI: 10.1186/ar3706  0.64
2012 Juskewitch JE, Knudsen BE, Platt JL, Nath KA, Knutson KL, Brunn GJ, Grande JP. LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. The American Journal of Pathology. 180: 32-40. PMID 22067909 DOI: 10.1016/j.ajpath.2011.10.001  0.64
2011 Krause ML, Davis JM, Knutson KL, Strausbauch MA, Strausbach MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis. Clinical Immunology (Orlando, Fla.). 141: 67-72. PMID 21703930 DOI: 10.1016/j.clim.2011.05.008  0.64
2011 Erskine CL, Krco CJ, Hedin KE, Borson ND, Kalli KR, Behrens MD, Heman-Ackah SM, von Hofe E, Wettstein PJ, Mohamadzadeh M, Knutson KL. MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 316-24. PMID 21613617 DOI: 10.4049/jimmunol.1100658  0.64
2011 Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Research. 71: 4707-19. PMID 21555371 DOI: 10.1158/0008-5472.CAN-10-4554  0.64
2011 Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H, Goode EL, Kalli KR, Knutson KL. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 186: 6905-13. PMID 21551365 DOI: 10.4049/jimmunol.1100274  0.64
2011 Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 3: 539-56. PMID 21463194 DOI: 10.2217/imt.11.20  0.64
2011 Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis and Rheumatism. 63: 1497-506. PMID 21384332 DOI: 10.1002/art.30323  0.64
2011 White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes & Control : Ccc. 22: 785-801. PMID 21359843 DOI: 10.1007/s10552-011-9745-4  0.64
2010 Karyampudi L, Knutson KL. Antibodies in cancer immunotherapy. Cancer Biomarkers : Section a of Disease Markers. 6: 291-305. PMID 20938089 DOI: 10.3233/CBM-2009-0141  0.64
2010 Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: A pilot clinical trial Journal of Translational Medicine. 8. PMID 20529245 DOI: 10.1186/1479-5876-8-53  0.64
2010 Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Matteson EL, Gabriel SE. Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. Journal of Immunology (Baltimore, Md. : 1950). 184: 7297-304. PMID 20495063 DOI: 10.4049/jimmunol.0904180  0.64
2010 Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: Dependence on TCR:Peptide-MHC interaction, ICAM-1, IL-12, and IFN-{gamma} (The Journal of Immunology (2007) 178, (3583-3592)) Journal of Immunology. 184: 6555. PMID 20483795 DOI: 10.4049/jimmunol.1090034  0.64
2010 Reiman JM, Knutson KL, Radisky DC. Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells Cancer Research. 70: 3005-3008. PMID 20395197 DOI: 10.1158/0008-5472.CAN-09-4041  0.64
2010 Taylor JA, Cummins NW, Bren GD, Rizza SA, Kolbert CP, Behrens MD, Knutson KL, Kahl JC, Asmann YW, Badley AD. Casp8p41 expression in primary T cells induces a proinflammatory response. Aids (London, England). 24: 1251-8. PMID 20299954 DOI: 10.1097/QAD.0b013e3283389e90  0.64
2010 Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunology, Immunotherapy : Cii. 59: 943-53. PMID 20140431 DOI: 10.1007/s00262-010-0820-6  0.64
2010 Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 825-34. PMID 20103660 DOI: 10.1158/1078-0432.CCR-09-2781  0.64
2010 Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells Breast Cancer Research and Treatment. 123: 39-49. PMID 19898981 DOI: 10.1007/s10549-009-0622-8  0.64
2010 Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, ... Knutson KL, et al. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunology, Immunotherapy : Cii. 59: 161-71. PMID 19621224 DOI: 10.1007/s00262-009-0738-z  0.64
2009 Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS, Knutson KL. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. Plos One. 4: e6292. PMID 19617914 DOI: 10.1371/journal.pone.0006292  0.64
2009 Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma Gastroenterology. 137: 1270-1279. PMID 19577568 DOI: 10.1053/j.gastro.2009.06.053  0.64
2009 White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, Schildkraut JM, Cunningham JM, Kelemen LE, Pankratz VS, Rider DN, Liebow M, Hartmann LC, Sellers TA, Goode EL. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. Bmc Cancer. 9: 170. PMID 19500386 DOI: 10.1186/1471-2407-9-170  0.64
2009 Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Research. 69: 2887-95. PMID 19276366 DOI: 10.1158/0008-5472.CAN-08-3343  0.64
2008 Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Research. 68: 4893-901. PMID 18559537 DOI: 10.1158/0008-5472.CAN-07-6726  0.64
2008 Worschech A, Kmieciak M, Knutson KL, Bear HD, Szalay AA, Wang E, Marincola FM, Manjili MH. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Research. 68: 2436-46. PMID 18381452 DOI: 10.1158/0008-5472.CAN-07-6822  0.64
2008 Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology. 108: 619-26. PMID 18222534 DOI: 10.1016/j.ygyno.2007.11.020  0.64
2008 Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL. The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood. 111: 1472-9. PMID 18029553 DOI: 10.1182/blood-2007-10-117184  0.64
2007 Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5133-43. PMID 17785568 DOI: 10.1158/1078-0432.CCR-07-0507  0.64
2007 Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression Seminars in Cancer Biology. 17: 275-287. PMID 17662614 DOI: 10.1016/j.semcancer.2007.06.009  0.64
2007 Tracz MJ, Juncos JP, Grande JP, Croatt AJ, Ackerman AW, Rajagopalan G, Knutson KL, Badley AD, Griffin MD, Alam J, Nath KA. Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice American Journal of Pathology. 170: 1820-1830. PMID 17525251 DOI: 10.2353/ajpath.2007.061093  0.64
2007 Siddiqui SA, Frigola X, Bonne-Annee S, Mercader M, Kuntz SM, Krambeck AE, Sengupta S, Dong H, Cheville JC, Lohse CM, Krco CJ, Webster WS, Leibovich BC, Blute ML, Knutson KL, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2075-81. PMID 17404089 DOI: 10.1158/1078-0432.CCR-06-2139  0.64
2007 Dang Y, Knutson KL, Goodell V, Dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML. Tumor antigen - Specific T-cell expansion is greatly facilitated by in vivo priming Clinical Cancer Research. 13: 1883-1891. PMID 17363545 DOI: 10.1158/1078-0432.CCR-06-2083  0.64
2007 Radhakrishnan S, Wiehagen KR, Pulko V, Van Keulen V, Faubion WA, Knutson KL, Pease LR. Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-12, and IFN-gamma. Journal of Immunology (Baltimore, Md. : 1950). 178: 3583-92. PMID 17339455  0.64
2007 Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses European Journal of Immunology. 37: 675-685. PMID 17304628 DOI: 10.1002/eji.200636639  0.64
2007 Nava-Parada P, Forni G, Knutson KL, Pease LR, Celis E. Peptide vaccine given with a toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors Cancer Research. 67: 1326-1334. PMID 17283170 DOI: 10.1158/0008-5472.CAN-06-3290  0.64
2007 Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis Cancer Immunology, Immunotherapy. 56: 271-285. PMID 16819631 DOI: 10.1007/s00262-006-0194-y  0.64
2006 Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Research. 66: 9754-61. PMID 17018635 DOI: 10.1158/0008-5472.CAN-06-1083  0.64
2006 Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, Low PS, Hartmann LC, Kalli KR. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4254-61. PMID 16908932 DOI: 10.1200/JCO.2006.05.9311  0.64
2006 Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Immunoediting of cancers may lead to epithelial to mesenchymal transition. Journal of Immunology (Baltimore, Md. : 1950). 177: 1526-33. PMID 16849459  0.64
2006 Knutson KL. Strong-arming immune regulation: Suppressing regulatory T-cell function to treat cancers Future Oncology. 2: 379-389. PMID 16787118 DOI: 10.2217/14796694.2.3.379  0.64
2006 Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 177: 84-91. PMID 16785502  0.64
2006 Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion Molecular Cancer Therapeutics. 5: 149-155. PMID 16432173 DOI: 10.1158/1535-7163.MCT-05-0206  0.64
2006 Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Research. 66: 1147-54. PMID 16424052 DOI: 10.1158/0008-5472.CAN-05-2289  0.64
2006 Knutson KL, Dela Rosa C, Disis ML. Laboratory analysis of T-cell immunity Frontiers in Bioscience. 11: 1932-1944. PMID 16368569  0.64
2006 Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Research and Treatment. 96: 233-41. PMID 16211331 DOI: 10.1007/s10549-005-9044-4  0.64
2006 Knutson KL, Wagner W, Disis ML. Adoptive T cell therapy of solid cancers Cancer Immunology, Immunotherapy. 55: 96-103. PMID 15891880 DOI: 10.1007/s00262-005-0706-1  0.64
2004 Disis ML, Salazar LG, Knutson KL. Peptide-based vaccines in breast cancer Breast Disease. 20: 3-11. PMID 15687702  0.64
2004 Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients Journal of Clinical Immunology. 24: 571-578. PMID 15359116 DOI: 10.1023/B:JOCI.0000040928.67495.52  0.64
2004 Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, ... ... Knutson KL, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine. 10: 942-9. PMID 15322536 DOI: 10.1038/nm1093  0.64
2004 Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, Dela Rosa C, Cheever MA. Effect of dose on immune response in patients vaccinated with an HER-2/neu intracellular domain protein-based vaccine Journal of Clinical Oncology. 22: 1916-1925. PMID 15143085 DOI: 10.1200/JCO.2004.09.005  0.64
2004 Knutson KL, Almand B, Dang Y, Disis ML. neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice Cancer Research. 64: 1146-1151. PMID 14871850 DOI: 10.1158/0008-5472.CAN-03-0173  0.64
2003 Disis ML, Schiffman K, Salazar LG, Almand B, Knutson KL. HER-2/neu vaccines Cancer Chemotherapy and Biological Response Modifiers. 21: 275-285. PMID 15338750  0.64
2003 Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. Immunization of Cancer Patients with HER-2/neu-Derived Peptides Demonstrating High-Affinity Binding to Multiple Class II Alleles Clinical Cancer Research. 9: 5559-5565. PMID 14654536  0.64
2003 Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellstrom̈ KE, Hellstrom̈ I. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity Molecular Cancer Therapeutics. 2: 995-1002. PMID 14578464  0.64
2003 Knutson KL, Curiel TJ, Salazar L, Disis ML. Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematology/Oncology Clinics of North America. 17: 1051-73. PMID 12959191 DOI: 10.1016/S0889-8588(03)00064-9  0.64
2003 Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens Immunobiology. 207: 179-186. PMID 12777059 DOI: 10.1078/0171-2985-00230  0.64
2003 Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Medicine. 9: 562-7. PMID 12704383 DOI: 10.1038/nm863  0.64
2003 McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. Journal of Clinical Immunology. 23: 62-72. PMID 12645861 DOI: 10.1023/A:1021904432489  0.64
2002 Knutson KL, Bishop MR, Schiffman K, Disis ML. Immunotherapy for breast cancer Cancer Chemotherapy and Biological Response Modifiers. 20: 351-369. PMID 12703214  0.64
2002 Knutson KL. Technology evaluation: DCVax, Northwest biotherapeutics Current Opinion in Molecular Therapeutics. 4: 403-407. PMID 12222879  0.64
2002 Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient Human Immunology. 63: 547-557. PMID 12072190 DOI: 10.1016/S0198-8859(02)00401-9  0.64
2002 Knutson KL. GMK: Progenics pharmaceuticals Current Opinion in Investigational Drugs. 3: 159-164. PMID 12054067  0.64
2002 Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2624-32. PMID 12039923 DOI: 10.1200/JCO.2002.06.171  0.64
2002 Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Clinical Cancer Research. 8: 1014-1018. PMID 12006513  0.64
2002 Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood. 99: 2845-50. PMID 11929774 DOI: 10.1182/blood.V99.8.2845  0.64
2002 Knutson KL, Almand B, Mankoff DA, Schiffman K, Disis ML. Adoptive T-cell therapy for the treatment of solid tumours Expert Opinion On Biological Therapy. 2: 55-66. PMID 11772340 DOI: 10.1517/14712598.2.1.55  0.64
Show low-probability matches.